Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Weining Z. Robieson"'
Autor:
Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala, Maurizio F. Facheris, Victor S. C. Fung
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 1937-1958 (2023)
Abstract Introduction Foslevodopa/foscarbidopa, a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs for the treatment of Parkinson’s disease (PD), is administered as a 24-hour/day continuous subcutaneous infusion (CSCI) with a single infus
Externí odkaz:
https://doaj.org/article/3c28527413ce4845845ba7b0a3dbeb25
Autor:
Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala, Maurizio F. Facheris, Victor S. C. Fung
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 1959-1960 (2023)
Externí odkaz:
https://doaj.org/article/fbd221fdae034683822ddee813fd4949
Autor:
James T. Boyd, Cindy Zadikoff, Janet A. Benesh, Jorge Zamudio, Weining Z. Robieson, Pavnit Kukreja, Masayuki Yokoyama, Mustafa S. Siddiqui
Publikováno v:
Clinical Parkinsonism & Related Disorders, Vol 2, Iss , Pp 25-34 (2020)
Introduction: As Parkinson's disease (PD) progresses, the number/frequency of PD medications tend to increase, which is correlated with decreased patient compliance and suboptimal control of PD symptoms. We investigated efficacy and safety of levodop
Externí odkaz:
https://doaj.org/article/0aaba9c46e2842f084599e752bb59234
Autor:
Sun Ju Chung, Matilde Calopa, Maria G. Ceravolo, Nicola Tambasco, Angelo Antonini, K. Ray Chaudhuri, Weining Z. Robieson, Olga Sánchez-Soliño, Cindy Zadikoff, Man Jin, Luigi M. Barbato
Publikováno v:
Parkinson's Disease, Vol 2022 (2022)
Background. Nonmotor symptoms (NMS) are common in advanced Parkinson’s disease (APD) and reduce health-related quality of life. Objective. The aim of the study was to evaluate levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatm
Externí odkaz:
https://doaj.org/article/a578f099bea44185813cc8cb510cafe0
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Background: Levodopa-carbidopa intestinal gel (LCIG) is a long-term therapy for motor fluctuations in patients with advanced Parkinson's disease (PD). The aim of this analysis was to identify the baseline characteristics that predict “Off” time r
Externí odkaz:
https://doaj.org/article/40964afa6d8044f3ae7afdf26c684bbd
Autor:
Cindy Zadikoff, Werner Poewe, James T. Boyd, Lars Bergmann, Horia Ijacu, Pavnit Kukreja, Weining Z. Robieson, Janet Benesh, Angelo Antonini
Publikováno v:
Parkinson's Disease, Vol 2020 (2020)
Background. Levodopa-carbidopa intestinal gel (LCIG) provides continuous levodopa administration and clinical benefits to patients with advanced Parkinson’s disease (PD). This report evaluates long-term safety and efficacy of high-dose LCIG in PD p
Externí odkaz:
https://doaj.org/article/6f50c99361074ba09bc15f85b7ceb9b9
Autor:
Miho Murata, Masahito Mihara, Kazuko Hasegawa, Beomseok Jeon, Chon-Haw Tsai, Noriko Nishikawa, Tomoko Oeda, Masayuki Yokoyama, Weining Z. Robieson, Krai Chatamra, Maurizio F. Facheris, Janet Benesh
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 11 (2018)
Objectives: Levodopa-carbidopa intestinal gel (LCIG) was developed to reduce motor complications in Parkinson’s disease (PD) caused by pulsatile levodopa plasma concentrations following oral levodopa administration. Dyskinesia and ‘wearing off’
Externí odkaz:
https://doaj.org/article/f2b425b4f7d24f548b32e1f105db7879
Autor:
Marieta Anca-Herschkovitsch, Weining Z. Robieson, Norbert Kovács, Jason Aldred, David G. Standaert, Lars Bergmann, K. Ray Chaudhuri, Pavnit Kukreja, Francesco E. Pontieri, Mihaela Simu, Esther Cubo, Thomas L. Davis, Robert Iansek, Mustafa S. Siddiqui, Paul Bourgeois
Publikováno v:
Movement Disorders Clinical Practice
Background Levodopa‐carbidopa intestinal gel (LCIG) is an established treatment for improving motor and some non‐motor symptoms (NMS) in patients with advanced Parkinson's disease (PD). Prospective long‐term data in routine clinical practice ar
Autor:
Michael J Soileau, Jason Aldred, Kumar Budur, Nahome Fisseha, Victor SC Fung, Anna Jeong, Thomas E Kimber, Kevin Klos, Irene Litvan, Daniel O'Neill, Weining Z Robieson, Meredith A Spindler, David G Standaert, Saritha Talapala, Eleni Okeanis Vaou, Hui Zheng, Maurizio F Facheris, Robert A Hauser
Publikováno v:
The Lancet. Neurology. 21(12)
Levodopa is the most effective symptomatic therapy for Parkinson's disease, but patients with advanced Parkinson's disease develop motor fluctuations with chronic oral levodopa therapy. Foslevodopa-foscarbidopa is a soluble formulation of levodopa an
Autor:
Xin Huang, Tengfei Li, Qi Guo, Liuqing Yang, Dustin Wooten, Xifeng Wang, Weining Z. Robieson, Yan Sun, Scott Gladstein
Publikováno v:
Statistics in Biopharmaceutical Research. 13:337-343
The progression of Alzheimer’s disease (AD) is a continuous process in cognitive and biomarker changes, with only a fraction of mild cognitive impairment (MCI) patients eventually advancing to AD. ...